Analyst Reco. Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.47 ^USD	-1.40%		-6.92%	+162.23%

Apr. 10	Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes	CI
Mar. 18	Arcutis Biotherapeutics, Inc.(NasdaqGS:ARQT) added to S&P Biotechnology Select Industry Index	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mizuho Securities Raises Price Target on Arcutis Biotherapeutics to $17 From $16, Maintains Buy Rating	Feb. 28	MT
Needham Raises Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating	Feb. 28	MT
Mizuho Increases Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating	Feb. 23	MT
Mizuho Upgrades Arcutis Biotherapeutics to Buy From Neutral, Raises Price Target to $8 From $4	Jan. 03	MT
Exchange-Traded Funds Mixed; US Equities Rise Pre-Bell Monday as Investors Hope for Federal Reserve Rate Cuts Soon	Dec. 18	MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $10 From $45, Maintains Overweight Rating	Nov. 13	MT
JonesTrading Downgrades Arcutis Biotherapeutics to Hold From Buy	Nov. 08	MT
Needham Adjusts Price Target on Arcutis Biotherapeutics to $8 From $22, Maintains Buy Rating	Nov. 06	MT
Mizuho Downgrades Arcutis Biotherapeutics to Neutral From Buy	23-10-27	MT
Goldman Sachs Downgrades Arcutis Biotherapeutics to Neutral From Buy, Adjusts Price Target to $6 From $32	23-10-13	MT
Truist Securities Lowers Price Target on Arcutis Biotherapeutics to $40 From $45, Maintains Buy Rating	23-05-26	MT
Goldman Sachs Adjusts Price Target on Arcutis Biotherapeutics to $33 From $44, Maintains Buy Rating	23-05-11	MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $45 From $47, Maintains Overweight Rating	23-05-10	MT
Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $57 From $61, Maintains Buy Rating	23-05-10	MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $47 From $50, Keeps Overweight Rating	23-04-12	MT
Truist Securities Lowers Arcutis Biotherapeutics' Price Target to $45 From $50, Maintains Buy Rating	23-03-28	MT
Needham Adjusts Price Target on Arcutis Biotherapeutics to $24 From $46, Maintains Buy Rating	23-03-16	MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $50 From $51, Maintains Overweight Rating	23-03-01	MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $51 From $49, Maintains Overweight Rating	22-12-13	MT
Morgan Stanley Adjusts Arcutis Biotherapeutics' Price Target to $49 from $46, Maintains Overweight Rating	22-10-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Analyst Reco.

Filters